Supplemental Experimental Procedures
wall and then inserting 30 G stainless steel tubing. The 30 G stainless tubing was angled and advanced into the 18 G tubing so as to be centered within the larger tubing and then soldered in place. Tubing connectors were attached to the chamber inlets by successively soldering 23 G and 27 G stainless steel tubing in place. Polyethylene tubing (PE10 Intramedic tubing, Becton Dickinson and Company) was attached to the chamber inlets for connection to the syringes. Drug or prodrug in organic solvent and aqueous solution (1:10 by volume) were pumped in a colliding direction, creating a turbulent mixing flow.
Prodrug Lability
Lability studies for PI, RRH-PI derivatives, melphalan, and V were conducted on a Cary Eclipse Fluorescence Spectrophotometer (Varian Inc.). To solutions of PI or RRH-PI-prodrugs (7.48 µM in DMSO) were added various amounts of buffer (25μL, 50μL, and 100μL of 20 mM Hepes buffer) at two different pH's (pH 8.5 and pH 7.2). Upon cleavage of the hydrophobic modification and regeneration of PI, the fluorescence of the solution increased (λ ex = 493 nm, λ em = 647 nm, excitation and emission slit width = 5 nm, and emission PMT = 600V) and was assayed as a function of time (20 minutes). Alternatively, to solutions of fluorescamine (857 µM in DMSO) were added various amounts of buffer (20μL, 30μL, 40μL, 50μL, and 70μL of 100 mM MES buffer, pH 6.0) followed by melphalan or V (249 µM final concentration in DMSO).
The fluorescence of the solution (λ ex = 380 nm, λ em = 464 nm, excitation and emission slit width = 5 nm, and emission PMT = 600V) was assayed as a function of time (40 minutes). At each buffer concentration the reaction of fluorescamine and melphalan was more rapid than hydrolytic breakdown of V. The resulting curves were normalized for intensity and fit to an exponential equation (Origin) to determine k determined for each solution. The k determined for each compound at appropriate pH were plotted against the mol% of H 2 O, and the best fit line was solved for k buffer for 100 mol% H 2 O. These derived k buffer values were used to determine the half-life of the prodrug in pure buffer according to the equation t 1/2 =ln2/k.
In Vitro Cellular Uptake
Compound IV was mixed with PI and then delivered to SKOV-3 cells, and the cells were imaged as previously described. In one protocol, equal amounts of IV (15.0 mM in DMSO) and PI (15.0 mM in DMSO) were combined and the resulting solution was added to cells via the mixing chamber. In a second method, PI was taken up in the ITG solution (0.748 mM) and mixed with IV (7.48 mM in DMSO) in the mixing chamber. Similarly, V (15 mM and 30 mM in DMSO) was mixed with PI and delivered to Hepa 1-6 and SKOV-3 cells using the second method. The cells were imaged as before following 30 sec -4 min exposure to the drug solution.
For experiments conducted on Jurkat cells (8.0 x 10 5 cells / ml in media), the cells were isolated by centrifugation and resuspended in ITG at a density of 4.0 x 10 6 cells / ml. Exposure to the drug / prodrug was conducted by passing the cells in suspension in ITG (200 µl) through the mixing chamber. After 30 sec. the cells were centrifuged and the drug solution was removed (aspirated), the cells were resuspended in complete media (2 ml) and plated in 6-well plates for imaging. Passing the cells through the mixing chamber (no drug / prodrug treatment) had no effect on cell viability when compared to cells plated without passing through the mixing chamber. 
In Vivo Studies
Liver tumors models were established in C57BL mice using MC38 (colon carcinoma) and Hepa 1-6 (hepatoma), in BALB/c mice using B16 (melanoma), and in A/J mice using NXS2 The amount of PI retained in hepatocytes was also quantitated following intraportal injections of PI and II. The isolated hepatocyte suspensions were dissolved in 0.5% octyl glycoside in 10 mM HEPES buffer, pH 7.5. Nucleic acid was then isolated from cell suspensions (0.5 ml) using phenol extraction. PI fluorescence spectra were monitored (Shimadzu RF 1501
Spectrophotometer) using an excitation wavelength of 530 nm and an emission wavelength of 617 nm. All spectra were background subtracted using the fluorescence of cell suspensions from untreated animals. PI calibration curves were generated by mixing increasing amounts of PI in each of the samples. The obtained curves were linear, indicating that PI binding to nucleic acid in the samples was not saturated, and the fluorescence was a result of nucleic acid bound PI and not free PI, thus allowing for determination of the amount of PI present in the samples. The amount of PI uptake was then calculated according to the equation: Amt(%) = 100 x PI s / PI i , where PI s is the amount of PI in the cell suspension and PI i is the amount of PI or BDMOD-PI injected (corrected for the sample size relative to the total liver).
